AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$TWST

Leproust Emily M. sold $56.3M of TWST

Leproust Emily M. (Chief Executive Officer) sold 356,546 shares of Twist Bioscience Corp (TWST) at an average of $157.99 ($151.46–$163.39, $56.33M total) across 13 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Sep 21, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
high confidence
Mentioned
$TWST
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishMed
01

Why it matters

The reduction in insider ownership may be interpreted as reduced confidence, influencing short‑term price action.

02

Market read

Primary insider sell of significant size; traders may consider adjusting positions in TWST.

03

What to watch

Potential tax planning or diversification motives for the CEO; no immediate operational concerns.

Relevance 7/10Novelty 7/10Timing: post‑market 2026‑09‑21

Background

Form 4 filings disclose insider transactions; a $56M sell by the CEO is noteworthy for investors.

Company-level read

Ticker impact

$TWSTBearishHigh confidence
Context

CEO Emily Leproust sold 356,546 shares for $56.3M via a 10b5‑1 plan, reducing her stake to 620,589 shares.

Expected impact

Potential short‑term dip as market digests the sizable sell‑off.

Evidence & confidence

The transaction size ($56M) is material for a mid‑cap biotech and is disclosed via a primary Form 4 filing.

Market effects

Sector

May prompt scrutiny of other biotech insider activity and could affect sector sentiment.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global impact beyond TWST shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • person
    Emily M. Leproust

    Chief Executive Officer of Twist Bioscience Corp.

  • company
    Twist Bioscience Corp.

    Biotech company listed on NASDAQ under ticker TWST.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 19
$TWSTHigh

TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 7.1% following a deal with Eli Lilly for AI-driven drug discovery. Analysts see strong short-term momentum, with price targets at $160 (Leerink) and $144 (UBS). The company has high revenue growth but remains unprofitable, with Q3 free cash flow at -$8.6M. Balance sheet is stable, with a current ratio of 2.7.

timothysykes.com2 min
SEP 19
$TWSTMed

TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal

Twist Bioscience (TWST) stock rose 7.1% after securing an AI deal with Eli Lilly. The company reported $377M revenue, 52% gross margin, and -31.8% EBIT margin. Analysts highlight its AI-driven drug discovery capabilities but note persistent losses and rich valuation at 24x sales. Technical analysis suggests strong bullish momentum with support at $155.

timothysykes.com2 min
SEP 17
$TWSTMed

TWST Stock Hits Multi-Year High, But ‘Pharma Bro’ Martin Shkreli Calls Twist A Short

Twist Bioscience (TWST) stock reached a multi-year high, closing near $156 after a partnership with Eli Lilly's TuneLab and a price target increase from Leerink to $160. The company raised its fiscal 2026 sales guidance to $456M-$457M and aims for adjusted earnings break-even in Q4. Martin Shkreli called TWST a short, despite the surge. TWST's market cap exceeded $10B, with YTD gains of 390%.

finance.yahoo.com2 min
SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min